Literature DB >> 24353122

A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography.

Harald Farnik1, Jochen Weigt2, Peter Malfertheiner2, Angela Grützmann3, Liebwin Gossner3, Mireen Friedrich-Rust1, Stefan Zeuzem1, Christoph Sarrazin1, Jörg G Albert1.   

Abstract

BACKGROUND AND STUDY AIMS: Direct retrograde cholangioscopy (DRC) may improve the diagnostic and therapeutic yield of endoscopic retrograde cholangiography (ERC) but safety, feasibility, and outcome are unknown. PATIENTS AND METHODS: All consecutive patients who underwent DRC at three tertiary endoscopy centers for inconclusive findings at ERC were included in this retrospective analysis. Ultraslim endoscopes (FujiFilm EG 530NP; Olympus GIF XP180; GIF N180) were used by the peroral route for intubating all accessible bile ducts. Success rate, usefulness in diagnosis and therapy, and safety of DRC were assessed in terms of technical and clinical parameters and therapeutic vs. diagnostic indication.
RESULTS: DRC was performed in 130 cases (89 patients). CO2 insufflation and an anchoring balloon were used in 66.9% and 97.7% of cases, respectively. Intubation of the papilla was successful in 115 of 130 (88.5%) cases, and the aim of the DRC investigation was accomplished in 105 cases (80.8%). DRC-guided biopsies were taken in 53 cases (40.8%), and a therapeutic intervention was performed in 32 cases (24.6%). The initial diagnosis was revised by DRC in 18 of 69 patients (26.1%) with indeterminate biliary stricture. Complications were observed in 10 cases (7.7%), including cholangitis (n=2; 1.5%), bleeding (n=2; 1.5%), and pain, hypoxia, bradyarrhythmia, air embolism, and perforation of an intrahepatic and an extrahepatic bile duct (1 each; 0.8%). There was no mortality associated with DRC.
CONCLUSIONS: DRC was successfully performed for the diagnosis and treatment of biliary disease that had eluded diagnosis with conventional ERC. DRC impacted on clinical decision making. The complication rate was low and similar to other cholangioscopy techniques. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 24353122     DOI: 10.1055/s-0033-1359043

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  6 in total

Review 1.  Endoscopic Management of Difficult Bile Duct Stones.

Authors:  Murad Aburajab; Kulwinder Dua
Journal:  Curr Gastroenterol Rep       Date:  2018-03-23

Review 2.  Endoscopic Retrograde Cholangiopancreatography-Related Complications and Their Management Strategies: A "Scoping" Literature Review.

Authors:  Kemmian D Johnson; Abhilash Perisetti; Benjamin Tharian; Ragesh Thandassery; Priya Jamidar; Hemant Goyal; Sumant Inamdar
Journal:  Dig Dis Sci       Date:  2019-12-02       Impact factor: 3.199

Review 3.  Evaluation of indeterminate biliary strictures.

Authors:  Christopher L Bowlus; Kristin A Olson; M Eric Gershwin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-11-03       Impact factor: 46.802

4.  When in Trouble Think of the Bubble: Paradoxical Cerebral Arterial Gas Embolism after Endoscopic Retrograde Cholangiopancreatography.

Authors:  Konstantinos Ekmektzoglou; Georgios Alexandrakis; Konstantinos Dimopoulos; Panagiotis Tsibouris; Chrysostomos Kalantzis; Erasmia Vlachou; Periklis Apostolopoulos
Journal:  Case Rep Gastroenterol       Date:  2021-04-29

5.  The efficacy of peroral cholangioscopy for difficult bile duct stones and indeterminate strictures: a systematic review and meta-analysis.

Authors:  Praneet Korrapati; Jody Ciolino; Sachin Wani; Janak Shah; Rabindra Watson; V Raman Muthusamy; Jason Klapman; Srinadh Komanduri
Journal:  Endosc Int Open       Date:  2016-02-04

6.  CO2 or air cholangiography reduces the risk of post-ERCP cholangitis in patients with Bismuth type IV hilar biliary obstruction.

Authors:  Wen-Hui Zhang; Peng-Peng Ding; Lei Liu; Yan-Ling Wang; Wen-Hui Lai; Jing-Jing Han; Jun Han; Han-Wei Li
Journal:  BMC Gastroenterol       Date:  2020-06-15       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.